Literature DB >> 24304986

Pathogens causing blood stream infections and their drug susceptibility profile in immunocompromised patients.

Muhammad Fayyaz1, Irfan Ali Mirza, Aamer Ikram, Aamir Hussain, Tahir Ghafoor, Umer Shujat.   

Abstract

OBJECTIVE: To determine the types of pathogens causing blood stream infections and their drug susceptibility profile in immunocompromised patients. STUDY
DESIGN: Cross-sectional, observational study. PLACE AND DURATION OF STUDY: Department of Microbiology, Armed Forces Institute of Pathology, Rawalpindi, from January to September 2012.
METHODOLOGY: Blood culture bottles received from immunocompromised patients were dealt by two methods, brain heart infusion (BHI) broth based manual method and automated BACTEC system. The samples yielding positive growth from either of two methods were further analyzed. The identification of isolates was done with the help of biochemical reactions and rapid tests. Antimicrobial susceptibility of the isolates was carried out as per recommendations of Clinical and Laboratory Standards Institute (CLSI).
RESULTS: Out of the 938 blood culture specimens received from immunocompromised patients, 188 (20%) yielded positive growth. Out of these, 89 (47.3%) isolates were Gram positive and Gram negative each, while 10 (5.3%) isolates were fungi (Candida spp.). In case of Gram positive isolates, 75 (84.3%) were Staphylococcus spp. and 51 (67%) were Methicillin resistant. Amongst Gram negative group 49 (55.1%) isolates were of enterobacteriaceae family, while 40 (44.9%) were non-lactose fermenters (NLF). In vitro antimicrobial susceptibility of Staphylococci revealed 100% susceptibility to vancomycin and linezolid. The enterobacteriaceae isolates had better susceptibility against amikacin 85.7% compared to tigecycline 61.2% and imipenem 59.2%. For NLF, the in vitro efficacy of aminoglycosides was 72.5%.
CONCLUSION: The frequency of Gram positive and Gram negative organisms causing blood stream infections in immunocompromised patients was equal. Vancomycin in case of Gram positive and amikacin for Gram negative organisms revealed better in vitro efficacy as compared to other antibiotics.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24304986     DOI: 12.2013/JCPSP.848851

Source DB:  PubMed          Journal:  J Coll Physicians Surg Pak        ISSN: 1022-386X            Impact factor:   0.711


  5 in total

1.  Bloodstream infections and antimicrobial sensitivity patterns in a tertiary care hospital of India.

Authors:  Nikita Vasudeva; Prem Singh Nirwan; Preeti Shrivastava
Journal:  Ther Adv Infect Dis       Date:  2016-10-12

2.  Rare bacterial isolates causing bloodstream infections in Ethiopian patients with cancer.

Authors:  Balew Arega; Yimtubezinash Wolde-Amanuel; Kelemework Adane; Ezra Belay; Abdulaziz Abubeker; Daniel Asrat
Journal:  Infect Agent Cancer       Date:  2017-07-11       Impact factor: 2.965

3.  Evaluating the Trends of Bloodstream Infections among Pediatric and Adult Patients at a Teaching Hospital of Kathmandu, Nepal: Role of Drug Resistant Pathogens.

Authors:  Narayan Prasad Parajuli; Hridaya Parajuli; Roshan Pandit; Jyotsna Shakya; Puspa Raj Khanal
Journal:  Can J Infect Dis Med Microbiol       Date:  2017-04-06       Impact factor: 2.471

4.  Bacterial and fungal profile, drug resistance pattern and associated factors of isolates recovered from blood samples of patients referred to Ethiopian Public Health Institute: cross-sectional study.

Authors:  Etsehiwot Adamu Tsegaye; Dejenie Shiferaw Teklu; Zelalem Tazu Bonger; Abebe Aseffa Negeri; Tesfaye Legesse Bedada; Adane Bitew
Journal:  BMC Infect Dis       Date:  2021-11-29       Impact factor: 3.090

5.  Epidemiology and microbiology of Gram-positive bloodstream infections in a tertiary-care hospital in Beijing, China: a 6-year retrospective study.

Authors:  Qiang Zhu; Yan Yue; Lichen Zhu; Jiewei Cui; Minghui Zhu; Liangan Chen; Zhen Yang; Zhixin Liang
Journal:  Antimicrob Resist Infect Control       Date:  2018-09-03       Impact factor: 4.887

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.